Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine versus placebo in parvovirus-associated inflammatory cardiomyopathy
2016-004825-17Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in inflammatory cardiomyopathy and erythema infectiosum comparing Sebivo with Placebo (2 arms). Primary endpoint: Change in quality of life. Started Nov 2017; status: terminated.
02
Drugs
telbivudine
03
Conditions
inflammatory cardiomyopathyerythema infectiosum
Beyond the preview
Go deeper on 2016-004825-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004825-17.